The regulatory scrutiny facing direct-to-consumer telehealth platforms underscores the need for consumer vigilance regarding data privacy and recurring subscriptions. While compounded GLP-1 drugs significantly expanded affordable access during national shortages, transition to branded alternatives and stricter FTC enforcement requires patients to evaluate clinical oversight, recurring billing terms, and data-sharing agreements before signing up.
The FTC lawsuit against Hims & Hers highlights critical risks in telehealth data sharing, subscription billing, and compounded GLP-1 weight loss access.
The FTC, alongside California and Utah regulators, filed suit alleging Hims & Hers shared sensitive health data with ad networks like Meta and Snap, charged users prior to provider consultations, and used deceptive design practices that made subscription cancellations difficult.
Compounded GLP-1 drugs are legally permissible under federal law primarily during official FDA drug shortages. When supply shortages are resolved, rules for compounding custom formulations narrow, shifting platforms toward brand-name distribution models.
HIPAA does not automatically cover every direct-to-consumer health app. If a platform is not a designated covered entity or business associate, its data practices fall under FTC enforcement, leaving user tracking subject to commercial privacy policies.
To cancel a digital health subscription, locate the account management billing portal, submit a formal cancellation notice in writing to customer service, and retain confirmation records. If charges persist, notify your card issuer to dispute recurring billing.